| |
| |
|
| Insider
Information: |
Cittadine Andrew |
| Relationship: |
Chief Operating Officer |
| City: |
Wilmette |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
57,624 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$40,976 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
57,624 |
|
|
| Total
Value |
$40,976 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Monopar Therapeutics |
MNPR |
Chief Operating Officer |
2024-03-31 |
57,624 |
2022-06-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2024-03-31 |
4 |
D |
$0.68 |
$2,110 |
D/D |
(3,098) |
57,624 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,952 |
60,722 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-12-31 |
4 |
D |
$0.34 |
$1,054 |
D/D |
(3,098) |
51,770 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,952 |
54,868 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-09-30 |
4 |
D |
$0.62 |
$1,627 |
D/D |
(2,624) |
45,916 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,953 |
48,540 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-06-30 |
4 |
D |
$0.86 |
$3,469 |
D/D |
(4,057) |
39,587 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2023-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,841 |
43,644 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2022-12-31 |
4 |
D |
$2.37 |
$3,332 |
D/D |
(1,406) |
26,894 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• • – |
2022-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,062 |
28,300 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-11-15 |
4 |
B |
$3.15 |
$31,500 |
D/D |
10,000 |
24,238 |
2.74 |
% |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-11-14 |
4 |
B |
$3.00 |
$18,159 |
D/D |
6,053 |
14,238 |
2.74 |
% |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-09-30 |
4 |
D |
$1.52 |
$1,810 |
D/D |
(1,191) |
8,185 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,063 |
9,376 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-06-30 |
4 |
D |
$2.30 |
$6,465 |
D/D |
(2,812) |
5,313 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Operating Officer |
• – – |
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,125 |
8,125 |
0 |
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
